SCHEMBL6999742

SCHEMBL6999742

CCOC(=O)CCN(c1ccccc1)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 1/20 0.65
CAMK2A Q9UQM7 2/20 0.61
CAMK2G Q13555 1/20 0.60
KEAP1 Q14145 3/20 0.57
NFE2L2 Q16236 3/20 0.57
ALDH1A1 P00352 2/20 0.55
LMNA P02545 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
CNR1 P21554 1/20 0.55
CNR2 P34972 1/20 0.55
ESR1 P03372 1/20 0.52
NR3C1 P04150 1/20 0.52
PGR P06401 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
TSHR P16473 1/20 0.52
CYP2C19 P33261 1/20 0.52
MAPT P10636 3/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7004444 0.94 BMP1 (0.71) BMP1CAMK2ACAMK2GKEAP1NFE2L2
SCHEMBL7003241 0.94 KEAP1 (0.61) BMP1CAMK2ACAMK2GKEAP1NFE2L2
SCHEMBL7000752 0.89 KEAP1 (0.66) BMP1KEAP1NFE2L2ALDH1A1LMNA
SCHEMBL7004788 0.82 BMP1 (0.66) BMP1ALDH1A1CNR1CNR2KMT2A
SCHEMBL7003143 0.82 KEAP1 (0.71) KEAP1NFE2L2ALDH1A1LMNANPSR1
SCHEMBL7001405 0.81 BMP1 (0.89) BMP1CAMK2ACAMK2GKEAP1NFE2L2
SCHEMBL21407106 0.81 BMP1 (0.77) BMP1CAMK2ACAMK2GKEAP1NFE2L2
SCHEMBL7001435 0.81 BMP1 (0.67) BMP1ALDH1A1TP53
SCHEMBL7005000 0.81 KEAP1 (0.50) BMP1CAMK2ACAMK2GKEAP1NFE2L2
SCHEMBL20314689 0.81 ESR1 (0.71) BMP1CAMK2ACAMK2GKEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191309-A1 N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production HO WEN-BIN (US) 2003-10-09 US disclosed
EP-1154992-A4 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN INC (US) 2003-05-28 EP disclosed
US-6506936-B1 Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases FIBROGEN, INC. 2003-01-14 US disclosed
EP-1154992-A1 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN, INC. (US) 2001-11-21 EP disclosed
WO-2000050390-A1 N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION FIBROGEN, INC. (US) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191309-A1 N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production MMP1, MMP13, COL14A1 BMP1 730/4885CAMK2A 1239/4885CAMK2G 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.